Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sight Sciences's annualized net income for the quarter that ended in Mar. 2024 was $-65.06 Mil. Sight Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $114.71 Mil. Therefore, Sight Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -56.72%.
The historical rank and industry rank for Sight Sciences's Return-on-Tangible-Equity or its related term are showing as below:
SGHT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -87.9 Med: -43.98 Max: -39.64
Current: -42.84
During the past 6 years, Sight Sciences's highest Return-on-Tangible-Equity was -39.64%. The lowest was -87.90%. And the median was -43.98%.
SGHT's Return-on-Tangible-Equity is ranked worse than 72.14% of 761
companies
in the Medical Devices & Instruments industry
Industry Median: 1.4
vs SGHT: -42.84
Sight Sciences Return-on-Tangible-Equity Historical Data
The historical data trend for Sight Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sight Sciences's Return-on-Tangible-Equity
For the Medical Devices subindustry, Sight Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sight Sciences Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Sight Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Sight Sciences (Sight Sciences) Business Description
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGHT has been successfully added to your 